Skip to main content
Equibles
SABS logo

SABS · SAB Biotherapeutics, Inc.

Track SABS — free

Use SABS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$3.72 +0.00 (+0.00%) At close · Sep 4
Russell 2000 member Rebalance outlook locked
Market Cap
$338.47M
Shares
90.99M

SABS metrics

52 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$3.72
Market cap
$338.47M

Price action

19 metrics
Price change (1W)
-5.3%
Price change (30D)
-1.3%
Price change (3M)
+7.2%
Price change (6M)
-2.4%
Price change (YTD)
-0.5%
Price change (1Y)
+60.3%
Trailing year
Price change (5Y)
—
52-week high
$4.59
52-week low
$1.95
Change from 52-week high
-19.0%
Change from 52-week low
+90.8%
Annualized volatility
69.9%
Beta
1.2
RSI (14D)
48.6
Price vs SMA 50
-0.4%
Price vs SMA 200
-2.6%
Avg volume (3M)
656,272
Relative volume
0.3
Average dollar volume
$2.47M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
90.99M

Valuation

12 metrics
P / E (TTM)
16.2
Trailing earnings · reciprocal yield 6.2%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
223.7×
reciprocal yield 0.4%
P / book
1.6
reciprocal yield 63.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-3.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$71.82M
Net income (TTM)
−$12.78M
Trailing 12 months
Diluted EPS (TTM)
$0.23
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+207.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.51M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+758.1%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-5.9%
Return on assets
-5.4%
Debt / equity
—
Current ratio
9.2
EBITDA (TTM)
−$68.85M
Free cash flow (TTM)
—
Quick ratio
9.2
Interest coverage
-309.8
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$102.63M
Latest balance sheet
Cash & equivalents
$8.27M
Total assets
$238.21M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$53.94M
Capital expenditures (TTM)
—
R&D (TTM)
$49.27M
SG&A (TTM)
—
Stock compensation (TTM)
$16.68M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
93
13F filer change QoQ
+10
Institutional ownership
76.6%

Short interest

3 metrics
Short interest
5.1%
Latest settlement · 11.0 days to cover
Days to cover
11.0d
Short-squeeze score
74 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1833214 CUSIP 78397T202 13F (30d) 75 filings 75 filers Visit website Investor relations